Key facts
- This page summarizes Jonathan E. Lim's Form 4 filing for Boundless Bio, Inc. (BOLD).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2024, 16:30.
Jonathan E. Lim - 02 Apr 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)
- Reporting relationship
- Director
- Issuer ticker
- BOLD
- Reported as of
- 02 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2024, 16:30:45 UTC
- Prior SEC filing
- 29 Mar 2024
- Next SEC filing
- 21 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jessica Oien, Attorney-in-Fact for Jonathan Lim
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan E. Lim filed Form 4 for Boundless Bio, Inc. (BOLD) on 04 Apr 2024.
Change
- Previous filing in this sequence was filed on 29 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BOLD
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +525,274
- Change %
- +2049%
- Price
- Shares after
- 550,915
- Date
- 02 Apr 2024
- Ownership
- By City Hill, LLC
- Footnotes
- F1, F2
BOLD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 102,564
- Date
- 02 Apr 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BOLD
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -512,820
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- By City Hill, LLC
- Underlying class
- Common Stock
- Underlying amount
- 512,820
- Exercise price
- Footnotes
- F1, F2
BOLD
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -5,128
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- By City Hill, LLC
- Underlying class
- Common Stock
- Underlying amount
- 5,128
- Exercise price
- Footnotes
- F1, F2
BOLD
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -7,326
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2024
- Ownership
- By City Hill, LLC
- Underlying class
- Common Stock
- Underlying amount
- 7,326
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
Footnote F2
Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.